Chenella F C, Gill M A, Kern J W, Floyd R A, McGehee W G
Am J Hosp Pharm. 1979 Jun;36(6):782-4.
Two methods of calculating heparin infusion rates for patients with venous thrombotic disease were compared; one method was based on a one-compartment pharmacokinetic model, the other on patient weight. Sixty-eight patients with presumed thromboembolic disease were started on continuous i.v. heparin sodium (porcine) using an infusion pump. Patients were divided into two groups--the infusion rate of Group I was based on patient weight (77 units/kg/4 hrs) and the infusion rate of Group 2 was determined by a pharmacokinetic equation based on a one-compartment heparin model. Heparin effect was measured by an activated partial thromboplastin time (APTT). The initial heparin infusion rate for Group 1 (4,784 +/- 672 units/4 hrs) was significantly greater (p less than 0.039, two-sample t-test) than that for Group 2 (4,413 +/- 779 units/4 hrs), but the variances of the rates were not significantly different (p = 0.40, ratio of variance F-test). Both methods for estimating initial heparin infusion rates gave mean APTT values in the center of the therapeutic range, but the variance in the APTTs of Group 2 patients was significantly smaller (p = 0.004) than that of Group 1. The pharmacokinetic model was more precise and reliable. This model should be valuable for insuring heparin's therapeutic effect without exposing patients to the potential risk of hemorrhage.
比较了两种计算静脉血栓形成疾病患者肝素输注速率的方法;一种方法基于一室药代动力学模型,另一种基于患者体重。68例疑似血栓栓塞性疾病的患者开始使用输液泵持续静脉输注猪源肝素钠。患者被分为两组——第一组的输注速率基于患者体重(77单位/千克/4小时),第二组的输注速率由基于一室肝素模型的药代动力学方程确定。通过活化部分凝血活酶时间(APTT)来测定肝素效果。第一组的初始肝素输注速率(4784±672单位/4小时)显著高于(p<0.039,双样本t检验)第二组(4413±779单位/4小时),但两组速率的方差无显著差异(p = 0.40,方差比F检验)。两种估算初始肝素输注速率的方法得出的平均APTT值均在治疗范围内,但第二组患者APTT的方差显著小于(p = 0.004)第一组。药代动力学模型更精确且可靠。该模型对于确保肝素的治疗效果而不使患者面临潜在出血风险应该是有价值的。